EV-associated biomarkers are more sensitive and accurate than other widely used biomarkers, such as carcinoembryonic antigen (CEA) for adenocarcinoma and prostate-specific antigen (PSA) for prostate cancer. This evidence concerns the gene CEACAM5 and prostate carcinoma.